Eli Lilly's Retatrutide Trial Shows 28.7% Weight Loss, Outperforming Tirzepatide
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: NASDAQ.COM
- Significant Weight Loss: In the latest phase 3 trial, patients taking a 12 mg dosage of Retatrutide lost an average of 28.7% of their body weight at the 68-week mark, significantly outperforming Tirzepatide's 26.6% in 2023, indicating Retatrutide's greater potential in the weight loss market and likely boosting Eli Lilly's market share.
- Pain Relief Discovery: More than 1 in 8 participants with obesity and knee osteoarthritis reported being completely pain-free by the end of the trial, enhancing Retatrutide's therapeutic value and potentially attracting broader insurance coverage, which could drive increased demand.
- Strong Revenue Growth: For the quarter ending September 30, 2025, Eli Lilly's revenue surged by 54% to $17.6 billion, with Mounjaro and Zepbound generating a combined $10.1 billion, underscoring the critical role of GLP-1 drugs in the company's financial performance.
- Huge Future Potential: Eli Lilly's ongoing development of GLP-1 drugs is expected to yield more indications, particularly for treating sleep apnea, and if approved, this will further enhance its product portfolio and solidify its market leadership.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1078 USD with a low forecast of 800.00 USD and a high forecast of 1300 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1077.190
Low
800.00
Averages
1078
High
1300
Current: 1077.190
Low
800.00
Averages
1078
High
1300
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
